Volume spike for NOXXON Pharma (ALNOX.PA) on EURONEXT 12 Mar 2026: active trading signals wider interest

ALNOX.PA stock is the most active name on EURONEXT intraday after a 10,209,655 share volume print on 12 Mar 2026. The price sits at €0.041, trading between €0.038 and €0.0466 today, with relative volume at 2.35x the norm. Traders are watching NOXXON Pharma N.V. (ALNOX.PA) because clinical partnerships and low quoted price create high intraday liquidity. This piece breaks the intraday drivers, key financial metrics, Meyka AI grading, and a short-term forecast to help active traders decide next steps.

ALNOX.PA stock: Intraday snapshot and volume details

NOXXON Pharma (ALNOX.PA) trades on EURONEXT in EUR with a last printed price of €0.041 and day range €0.038–€0.0466. Volume today reached 10,209,655 shares versus an average volume of 4,345,868, giving a relative volume of 2.35. The 50-day average price is €0.07 and the 200-day average is €0.18, showing the stock remains well below longer-term averages.

ALNOX.PA stock: What likely drove the most active session

The trading surge aligns with sustained market interest in NOXXON’s Spiegelmer pipeline and its collaboration with Merck on NOX-A12, a combination immuno-oncology program. Low quoted price and a thin public float often produce outsized intraday volume when clinical updates or analyst chatter appear. Market participants cite these fundamentals while institutional and retail liquidity converge, pushing activity without a large net price move today.

ALNOX.PA stock: Financials, valuation and balance-sheet strength

On reported metrics NOXXON shows EPS of -€0.22 and a negative PE of -0.19, reflecting clinical-stage losses. Cash per share is strong at €30.18 and book value per share is €14.33, supporting liquidity and a runway buffer. Key ratios: current ratio 1.84, debt/equity 0.54, and price-to-book 0.00 (price/book ~0.00), which indicate a market price far below accounting equity per share.

Meyka AI rates ALNOX.PA with a score out of 100 and technical outlook

Meyka AI rates ALNOX.PA with a score out of 100: 62.19 / 100 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecasts. Technically the short-term bias is neutral to slightly positive given the high intraday volume, but the price remains under both the 50-day and 200-day averages, which keeps momentum cautious.

ALNOX.PA stock: Risks and opportunities for traders

Primary upside stems from clinical progress and partner-led trials, which can re-rate a biotech quickly. Downside is binary: negative trial news, dilution, or funding gaps can compress price sharply. Working capital reported at roughly €4,427,000 and tangible assets near €4,498,000 reduce immediate insolvency risk, but continued R&D spending and interest coverage of -8.61 highlight ongoing cash burn concerns.

ALNOX.PA stock: Intraday trading approach and realistic price targets

For most-active intraday traders, use tight risk controls: monitor the €0.038 intraday low and €0.0466 high as immediate support and resistance. Short-term price targets for active scalps: €0.055 first target and €0.075 secondary target on sustained volume. Use stop-losses in percentage terms given the stock’s volatility and low nominal price to limit outsized losses.

Final Thoughts

ALNOX.PA stock posted a clear liquidity event on EURONEXT on 12 Mar 2026, with 10,209,655 shares traded and price anchored at €0.041. The company’s clinical pipeline and Merck collaboration remain the core fundamental drivers, while a strong cash-per-share figure (€30.18) provides an operational buffer. Meyka AI’s forecast model projects a 12-month price of €0.07, implying an upside of 70.73% from the current €0.041 level; forecasts are model-based projections and not guarantees. Given the proprietary grade 62.19/100 (B, HOLD), we see ALNOX.PA as a speculative trade for active traders, with upside tied to clinical news and downside tied to trial or financing risks. Active intraday traders should prioritise volume confirmation and tight stops, while longer-term investors should wait for clinical readouts or clearer funding signals. For more company details see the NOXXON website and the Meyka stock page for ALNOX.PA for live updates Meyka ALNOX.PA.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.